BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
June 03, 2024 00:00 ET
|
Biophta
COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement (via le...
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
June 03, 2024 00:00 ET
|
Biophta
PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the...
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
March 19, 2024 14:20 ET
|
Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
June 01, 2023 05:09 ET
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
$12+ Billion Diabetic Retinopathy Market Size to Grow at a CAGR of 6.5% by 2028 | The Insight Partners
October 19, 2022 10:09 ET
|
The Insight Partners
New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest market study on "Diabetic Retinopathy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19...
pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
June 13, 2017 07:00 ET
|
pSivida Corp
Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass.,...